64,816 Shares in Novo Nordisk A/S $NVO Acquired by Perpetual Ltd

Perpetual Ltd bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 64,816 shares of the company’s stock, valued at approximately $3,597,000.

Other large investors also recently added to or reduced their stakes in the company. NewSquare Capital LLC raised its holdings in shares of Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after buying an additional 282 shares during the period. Mid American Wealth Advisory Group Inc. acquired a new position in Novo Nordisk A/S in the 2nd quarter valued at about $37,000. State of Wyoming acquired a new position in Novo Nordisk A/S in the 1st quarter valued at about $38,000. Maseco LLP purchased a new stake in Novo Nordisk A/S during the second quarter worth about $39,000. Finally, Copeland Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after purchasing an additional 186 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NVO. HSBC restated a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, December 15th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and an average price target of $53.33.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $48.10 on Friday. The company has a market cap of $214.76 billion, a P/E ratio of 13.98 and a beta of 0.67. The firm has a fifty day moving average price of $49.84 and a 200 day moving average price of $57.59. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo filed an NDA with the U.S. FDA for once‑weekly CagriSema, a next‑generation combination obesity injection that showed superior Phase III weight‑loss results — a potential major booster to its obesity franchise if approved. Article Title
• Positive Sentiment: Novo is pursuing a higher 7.2 mg Wegovy dose after data showed stronger weight loss — this could help reclaim share versus rivals (e.g., Eli Lilly’s Zepbound) if approved and commercialized effectively. Article Title
• Positive Sentiment: Analyst/commentary pieces highlight upside from oral Wegovy development, supply‑chain fixes and restructuring that could materially improve margins and growth if execution continues. Article Title
• Positive Sentiment: Kepler Capital initiated/maintained a buy view (reported coverage), giving some buy‑side support to the shares. Article Title
• Neutral Sentiment: UBS reiterated a Neutral (Hold) rating and left its price target unchanged, signaling continued caution on competitive pressures despite product progress. Article Title
• Neutral Sentiment: Commentary pieces are reassessing Novo’s valuation after a steep, year‑long share decline; some see a longer runway to recovery while others point to durable competitive threats. Article Title
• Negative Sentiment: Novo issued profit warnings and underwent a CEO change earlier this year and cut guidance, contributing to a large YTD share decline; that operational uncertainty remains a drag on investor confidence. Article Title
• Negative Sentiment: Shares recently dipped more than the broader market after earnings/profitability concerns were flagged; short‑term volatility is likely to persist as investors weigh approvals vs competitive share losses. Article Title

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.